Primary cutaneous follicle centre lymphoma epidemiology and demographics: Difference between revisions
Mahshid |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overview== | ==Overview== | ||
The incidence of primary cutaneous follicle centre lymphoma increases with age; the median age at diagnosis is 51 years. Males are more commonly affected with primary cutaneous follicle centre lymphoma than females.<ref name=cancer.gov> Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 01, 2016</ref> | The incidence of primary cutaneous follicle centre lymphoma increases with age; the median age at diagnosis is 51 years. Males are more commonly affected with primary cutaneous follicle centre lymphoma than females.<ref name="cancer.gov"> Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 01, 2016</ref> | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Age=== | ===Incidence=== | ||
The incidence of primary cutaneous follicle centre lymphoma increases with age; the median age at diagnosis is 51 years.<ref name=cancer.gov> Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 01, 2016</ref> | |||
* The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
* In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
=== Prevalence === | |||
* The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
* In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
* The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | |||
=== Case-fatality rate/Mortality rate === | |||
* In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | |||
* The case-fatality rate/mortality rate of [disease name] is approximately [number range]. | |||
=== Age === | |||
* Patients of all age groups may develop [disease name]. | |||
* The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | |||
* [Disease name] commonly affects individuals younger than/older than [number of years] years of age. | |||
* [Chronic disease name] is usually first diagnosed among [age group]. | |||
* [Acute disease name] commonly affects [age group]. | |||
=== Race === | |||
* There is no racial predilection to [disease name]. | |||
* [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | |||
=== Gender === | |||
* [Disease name] affects men and women equally. | |||
* [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | |||
=== Region === | |||
* The majority of [disease name] cases are reported in [geographical region]. | |||
* [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
=== Developed Countries === | |||
=== Developing CountriesAge === | |||
The incidence of primary cutaneous follicle centre lymphoma increases with age; the median age at diagnosis is 51 years.<ref name="cancer.gov"> Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 01, 2016</ref> | |||
===Gender=== | ===Gender=== | ||
Males are more commonly affected with primary cutaneous follicle centre lymphoma than females.<ref name=cancer.gov> Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 01, 2016</ref> | Males are more commonly affected with primary cutaneous follicle centre lymphoma than females.<ref name="cancer.gov"> Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 01, 2016</ref> | ||
==References== | ==References== |
Revision as of 22:25, 24 October 2019
Primary cutaneous follicle centre lymphoma Microchapters |
Differentiating Primary cutaneous follicle centre lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary cutaneous follicle centre lymphoma epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Primary cutaneous follicle centre lymphoma epidemiology and demographics |
FDA on Primary cutaneous follicle centre lymphoma epidemiology and demographics |
CDC on Primary cutaneous follicle centre lymphoma epidemiology and demographics |
Primary cutaneous follicle centre lymphoma epidemiology and demographics in the news |
Blogs on Primary cutaneous follicle centre lymphoma epidemiology and demographics |
Directions to Hospitals Treating Splenic marginal zone lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
The incidence of primary cutaneous follicle centre lymphoma increases with age; the median age at diagnosis is 51 years. Males are more commonly affected with primary cutaneous follicle centre lymphoma than females.[1]
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing CountriesAge
The incidence of primary cutaneous follicle centre lymphoma increases with age; the median age at diagnosis is 51 years.[1]
Gender
Males are more commonly affected with primary cutaneous follicle centre lymphoma than females.[1]
References
- ↑ 1.0 1.1 1.2 Primary cutaneous follicle centre lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf5ae3e27c3994bd549b/. Accessed on March 01, 2016